key: cord-1034848-izuo0lbg
authors: Keeton, Roanne; Richardson, Simone I.; Moyo-Gwete, Thandeka; Hermanus, Tandile; Tincho, Marius B.; Benede, Ntombi; Manamela, Nelia P.; Baguma, Richard; Makhado, Zanele; Ngomti, Amkele; Motlou, Thopisang; Mennen, Mathilda; Chinhoyi, Lionel; Skelem, Sango; Maboreke, Hazel; Doolabh, Deelan; Iranzadeh, Arash; Otter, Ashley D.; Brooks, Tim; Noursadeghi, Mahdad; Moon, James; Grifoni, Alba; Weiskopf, Daniela; Sette, Alessandro; Blackburn, Jonathan; Hsiao, Nei-Yuan; Williamson, Carolyn; Riou, Catherine; Goga, Ameena; Garrett, Nigel; Bekker, Linda-Gail; Gray, Glenda; Ntusi, Ntobeko A.B.; Moore, Penny L.; Burgers, Wendy A.
title: Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant dependent manner
date: 2021-10-13
journal: Cell Host Microbe
DOI: 10.1016/j.chom.2021.10.003
sha: f0dc7655365492d14b50d56cebbb9ebce7d92f27
doc_id: 1034848
cord_uid: izuo0lbg

The Johnson and Johnson Ad26.COV2.S single dose vaccine represents an attractive option for COVID-19 vaccination in resource limited countries. We examined the effect of prior infection with different SARS-CoV-2 variants on Ad26.COV2.S immunogenicity. We compared participants who were SARS-CoV-2 naïve with those either infected with the ancestral D614G virus or infected in the second wave when Beta predominated. Prior infection significantly boosts spike binding antibodies, antibody-dependent cellular cytotoxicity and neutralizing antibodies against D614G, Beta and Delta, however neutralization cross-reactivity varied by wave. Robust CD4 and CD8 T cell responses are induced after vaccination, regardless of prior infection. T cell recognition of variants is largely preserved, apart from some reduction in CD8 recognition of Delta. Thus, Ad26.COV2.S vaccination following infection may result in enhanced protection against COVID-19. The impact of the infecting variant on neutralization breadth after vaccination has implications for the design of second-generation vaccines based on variants of concern.

. We established an observational study of 400 healthcare 10 workers (HCWs) with serial sampling since the first wave. We studied 60 HCWs who were 11 vaccinated in a Phase 3b implementation trial of single dose Ad26.COV2.S vaccine (Takuva 12 et al., 2021) . HCWs were recruited into three groups, namely those never infected with SARS-13

CoV-2 (n=20), and those with PCR-confirmed infection during the first wave (n=20) or second 14 wave (n=20) (Figure 1A and Supplemental Table S1 ). The Beta variant accounted for >90% 15 of infections in the Western Cape in the second wave ( Figure 1A) , making it likely that this 16 variant was responsible for infections in the latter group. Indeed, whole genome sequencing of 17 8/20 second wave participants confirmed infection with Beta. Serological profiles were 18 generated for each participant by measuring nucleocapsid and spike antibodies since July 2020 19 (3- prior infection, we observed a significant boost in neutralization after vaccination against 7 D614G and Beta (Figure 2A, Supplemental Figure S2A ). For first wave HCWs, titers were 8 boosted 13-fold from a GMT of 210 to 2,798 (Figure 2A) . Second wave HCWs were boosted 9 12-fold from a GMT of 99 to 1,157. To determine cross-reactivity of neutralizing antibodies, 10 we compared neutralization of D614G with Beta and Delta. For antibodies induced by 11 vaccination alone, all participants showed significantly lower titers against Beta (85% showing 12 no neutralization, GMT: 28) and Delta (78% showing no neutralization, GMT: 29). In both 13 groups of previously infected HCWs we saw cross-neutralization of Beta and Delta, but the 14 degree of cross-reactivity varied by wave of infection ( Figure 2B and C) . For HCWs infected 15 in the first wave, while neutralization of Beta and Delta was maintained, titers were 16 significantly lower for both VOCs (a reduction in GMT from 2,798 to 606 and 443, 17 respectively, compared to D614G). In contrast, plasma from those infected in the second wave 18 with Beta showed no significant difference in neutralization of D614G (GMT: 1157) but 6-fold 19 lower neutralization of Delta (GMT: 200, p<0.001) (Figure 2B and C) . Overall, prior infection 20 followed by vaccination triggered high titer neutralizing antibodies able to neutralize VOCs. 21

However, the pattern of neutralization varied by wave, suggesting that the neutralizing 22 antibody repertoire was shaped by the genotype of the infecting variant. We examined the effect of prior SARS-CoV-2 infection on vaccine T cell responses. We 3 measured intracellular cytokine production (IFN-, TNF- and IL-2) in response to peptides 4 covering the Wuhan-1 spike (Supplemental Figure S3A) . Vaccination induced spike-specific 5

CD4 and CD8 T cell responses in all groups (Figure 4A and B) . Infection-naive participants 6 or those infected in wave 1 had significantly higher CD4 T cell responses after vaccination 7 (median: 0.051 and 0.064, respectively). The wave 2 group had pre-existing responses that 8 were significantly higher than the first wave baseline infection responses, and mounted a more 9 modest response to vaccination, with similar medians (0.132% and 0.147%, p=ns). CD8 10 responses were present in fewer individuals prior to vaccination (15 and 32%, vs. 85 and 100% 11 for CD4 responses in first and second wave groups, respectively), and did not differ while CD8 T cells produced predominantly IFN- alone (Supplemental Figure S3C) , with no 20 significant difference in the profiles after vaccination for those who were infection naïve 21 compared to those with prior infection. 22

Finally, we assessed whether T cells induced by vaccination recognized Beta and Delta. We 23 tested spike peptides corresponding to the viral sequences of the ancestral strain, Beta or Delta 24 in 24 vaccinees. CD4 T cell recognition of Beta or Delta was fully preserved compared to the 25 ancestral strain (Figure 4D ). Spike-specific CD8 T cells (in 15/24 participants) cross-26 recognised Beta spike in 14/15 responders. In contrast, the median magnitude of the cytokine 27 response was significantly lower against Delta compared to Beta (p=0.041), and 8/15 (53%) of 28 CD8 responders had a two-fold or greater reduction in the response to Delta, including five 29 with complete loss of recognition ( Figure 4D) . Overall, these results demonstrate that robust 30

CD4 and CD8 T cell responses are generated after vaccination, regardless of prior infection. Therefore, while all participants were exposed to the same vaccine, the genotype of the 21 infecting virus determined the specificity of the responses, prior to vaccine boosting. These 

Further information and requests for resources and reagents should be directed to and will be 29 fulfilled by the lead contact, Wendy Burgers (wendy.burgers@uct.ac.za). 30 31

Materials will be made available by request to Wendy Burgers (wendy.burgers@uct.ac.za). The initial assembly obtained from Genome Detective was polished by aligning mapped reads 29 to the references and filtering out low-quality mutations using bcftools 1.7-2 mpileup method. Two μg/ml of spike protein were used to coat 96-well, high-binding plates and incubated 12 overnight at 4°C. The plates were incubated in a blocking buffer consisting of 5% skimmed 13 milk powder, 0.05% Tween 20, 1x PBS. Plasma samples were diluted to 1:100 starting dilution 14 in a blocking buffer and added to the plates. Secondary antibody was diluted to 1:3000 in 15 blocking buffer and added to the plates followed by TMB substrate (Thermofisher Scientific). 16

Upon stopping the reaction with 1 M H2SO4, absorbance was measured at a 450nm wavelength. 17

In all instances, mAbs CR3022 and BD23 were used as positive controls and palivizumab was 18 used as a negative control. All values were normalized with the CR3022 mAb. heat-inactivated plasma samples from vaccine recipients were incubated with the SARS-CoV-27 2 pseudotyped virus for 1 hour at 37°C, 5% CO2. Subsequently, 1x104 HEK 293T cells 28 engineered to over-express ACE-2 were added and incubated at 37°C, 5% CO2 for 72 hours 29 upon which the luminescence of the luciferase gene was measured. CB6 was used as a positive 30 control. 31

The ability of plasma antibodies to cross-link FcγRIIIa (CD16) and spike expressing cells was 1 measured as a proxy for antibody-dependent cellular cytotoxicity (ADCC). HEK293T cells 2 were transfected with 5μg of SARS-CoV-2 original variant spike (D614G), Beta or Delta spike 3 plasmids using PEI-MAX 40,000 (Polysciences) and incubated for 2 days at 37°C. Expression 4 of spike was confirmed by binding of CR3022 and P2B-2F6 and their detection by anti-IgG and moderately boosts T cell responses against variants of concern. Furthermore, the infecting virus spike sequence determines the cross-reactivity of neutralizing responses, with implications for second generation vaccine design.

Metropolitan sub-districts after the peak of infections. NICD COVID-19 Special Public 11

Structure-based design of prefusion-15 stabilized SARS-CoV-2 spikes

SARS-CoV-2 mRNA vaccines induce a 20 greater array of spike-specific antibody isotypes with more potent complement binding 21 capacity than natural infection

Decay of Fc-dependent antibody 25 functions after mild to moderate COVID-19

Reduced neutralization of SARS-CoV-2 B. 30 1.617 by vaccine and convalescent serum

Antibody response to 35 first BNT162b2 dose in previously SARS-CoV-2-infected individuals

CoV-2 T cell epitopes in unexposed humans

Correlates of protection against SARS-CoV-2 in 45 rhesus macaques

Single-shot Ad26 vaccine protects against 49

SARS-CoV-2 in rhesus macaques

S COVID-19 vaccine show reduced activity against 501Y.V2 (B. 1.351), 6 despite protection against severe disease by this variant

SARS-CoV-2 spike L452R variant evades cellular 11 immunity and increases infectivity

Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)

CoV-2 Sero-Epidemiological Survey and Estimated Infection Incidence and Fatality Risk in 22 Gauteng Province

Human B cell clonal expansion and 27 convergent antibody responses to SARS-CoV-2

CoV-2 variant Delta to antibody neutralization

Prior SARS-CoV-2 infection 37 rescues B and T cell responses to variants after first vaccine dose

Targeting Fc effector function in vaccine design

CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis 46 coinfection

Loss of recognition of SARS-CoV

351 variant spike epitopes but overall preservation of T cell immunity

Convergent antibody responses to 5 SARS-CoV-2 in convalescent individuals

Antigen-Specific Adaptive 10 Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease 11 Severity

Binding and neutralization antibody titers after a single vaccine dose in health 15 care workers previously infected with SARS-CoV-2

Safety and efficacy of single-dose 20

S vaccine against Covid-19

SARS-CoV-2-specific T cell responses and 25 correlations with COVID-19 patient predisposition

Antibody potency, effector 30 function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

mRNA vaccination boosts 35 cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Immunogenicity of the Ad26. 40 COV2. S Vaccine for COVID-19

Prevalence of anti-SARS-CoV-2 45 antibodies among blood donors in Northern Cape

Thromboembolic Events in the South African Ad26. 2 COV2. S Vaccine Study

Impact of SARS-CoV-2 variants on the total CD4(+) 7 and CD8(+) T cell reactivity in infected or vaccinated individuals

CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell 13 responses

Detection of a SARS-CoV-2 18 variant of concern in South Africa

Kinetics and correlates of 23 the neutralizing antibody response to SARS-CoV-2 infection in humans

Antibody resistance of SARS-CoV-2 variants B.1.351 and 28 B.1.1.7

Naturally enhanced neutralizing 32 breadth against SARS-CoV-2 one year after infection

SARS-CoV-2 37 501Y. V2 escapes neutralization by South African COVID-19 donor plasma

Human neutralizing antibodies against SARS-CoV-2 42 require intact Fc effector functions for optimal therapeutic protection

Compromised humoral functional evolution tracks 47 with SARS-CoV-2 mortality